India's Nicholas Piramal Signs Second Potential $100 Million R&D Deal with Lilly

NEW DELHI - The research unit of Indian firm Nicholas Piramal signed its second development deal with Eli Lilly Feb. 15, worth up to $110 million, to carry out clinical work on two unspecified drugs "directed against the same target" and participate in further studies, manufacturing and sales